Immunological differences between insect venom‐allergic patients with and without immunotherapy and asymptomatically sensitized subjects

Background Currently available tests are unable to distinguish between asymptomatic sensitization and clinically relevant Hymenoptera venom allergy. A reliable serological marker to monitor venom immunotherapy (VIT) does also not exist. Our aim was to find reliable serological markers to predict tol...

Full description

Saved in:
Bibliographic Details
Published inAllergy (Copenhagen) Vol. 73; no. 6; pp. 1223 - 1231
Main Authors Arzt, L., Bokanovic, D., Schrautzer, C., Laipold, K., Möbs, C., Pfützner, W., Herzog, S. A., Vollmann, J., Reider, N., Bohle, B., Aberer, W., Sturm, G. J.
Format Journal Article
LanguageEnglish
Published Denmark Blackwell Publishing Ltd 01.06.2018
Subjects
Online AccessGet full text
ISSN0105-4538
1398-9995
1398-9995
DOI10.1111/all.13368

Cover

Loading…
Abstract Background Currently available tests are unable to distinguish between asymptomatic sensitization and clinically relevant Hymenoptera venom allergy. A reliable serological marker to monitor venom immunotherapy (VIT) does also not exist. Our aim was to find reliable serological markers to predict tolerance to bee and vespid stings. Methods We included 77 asymptomatically sensitized subjects, 85 allergic patients with acute systemic sting reactions, and 61 allergic patients currently treated with VIT. Levels of sIgE and sIgG4 to bee and vespid venom, rApi m 1, and rVes v 5 were measured immediately after allergic sting reactions or before sting challenges and 4 weeks later. All sting challenges were tolerated. The inhibitory activity was determined using BAT inhibition and ELIFAB assay. Results Median sIgG4 levels were 96‐fold higher in VIT patients (P < .001) while sIgE/sIgG4 ratios were consistently lower (P < .001). The ELIFAB assay was paralleled by low sIgE/sIgG4 ratios in VIT patients, showing markedly higher allergen‐blocking capacity (P < .001). An almost complete inhibition of the basophil response was seen in all patients treated with vespid venom, but not in those treated with bee venom. Four weeks after the sting, sIgE and sIgG4 levels were increased in allergic and asymptomatically sensitized patients, but not in VIT patients. Conclusion Immunological responses after stings varied in bee and vespid venom‐allergic patients. In patients under VIT, sIgE and sIgG4 remained completely stable after sting challenges. Monitoring VIT efficacy was only possible in vespid venom allergy, and the sIgG4 threshold for rVes v 5 had the highest sensitivity to confirm tolerance. The BAT inhibition test was the most reliable tool to confirm tolerance on an individual basis.
AbstractList Currently available tests are unable to distinguish between asymptomatic sensitization and clinically relevant Hymenoptera venom allergy. A reliable serological marker to monitor venom immunotherapy (VIT) does also not exist. Our aim was to find reliable serological markers to predict tolerance to bee and vespid stings.BACKGROUNDCurrently available tests are unable to distinguish between asymptomatic sensitization and clinically relevant Hymenoptera venom allergy. A reliable serological marker to monitor venom immunotherapy (VIT) does also not exist. Our aim was to find reliable serological markers to predict tolerance to bee and vespid stings.We included 77 asymptomatically sensitized subjects, 85 allergic patients with acute systemic sting reactions, and 61 allergic patients currently treated with VIT. Levels of sIgE and sIgG4 to bee and vespid venom, rApi m 1, and rVes v 5 were measured immediately after allergic sting reactions or before sting challenges and 4 weeks later. All sting challenges were tolerated. The inhibitory activity was determined using BAT inhibition and ELIFAB assay.METHODSWe included 77 asymptomatically sensitized subjects, 85 allergic patients with acute systemic sting reactions, and 61 allergic patients currently treated with VIT. Levels of sIgE and sIgG4 to bee and vespid venom, rApi m 1, and rVes v 5 were measured immediately after allergic sting reactions or before sting challenges and 4 weeks later. All sting challenges were tolerated. The inhibitory activity was determined using BAT inhibition and ELIFAB assay.Median sIgG4 levels were 96-fold higher in VIT patients (P < .001) while sIgE/sIgG4 ratios were consistently lower (P < .001). The ELIFAB assay was paralleled by low sIgE/sIgG4 ratios in VIT patients, showing markedly higher allergen-blocking capacity (P < .001). An almost complete inhibition of the basophil response was seen in all patients treated with vespid venom, but not in those treated with bee venom. Four weeks after the sting, sIgE and sIgG4 levels were increased in allergic and asymptomatically sensitized patients, but not in VIT patients.RESULTSMedian sIgG4 levels were 96-fold higher in VIT patients (P < .001) while sIgE/sIgG4 ratios were consistently lower (P < .001). The ELIFAB assay was paralleled by low sIgE/sIgG4 ratios in VIT patients, showing markedly higher allergen-blocking capacity (P < .001). An almost complete inhibition of the basophil response was seen in all patients treated with vespid venom, but not in those treated with bee venom. Four weeks after the sting, sIgE and sIgG4 levels were increased in allergic and asymptomatically sensitized patients, but not in VIT patients.Immunological responses after stings varied in bee and vespid venom-allergic patients. In patients under VIT, sIgE and sIgG4 remained completely stable after sting challenges. Monitoring VIT efficacy was only possible in vespid venom allergy, and the sIgG4 threshold for rVes v 5 had the highest sensitivity to confirm tolerance. The BAT inhibition test was the most reliable tool to confirm tolerance on an individual basis.CONCLUSIONImmunological responses after stings varied in bee and vespid venom-allergic patients. In patients under VIT, sIgE and sIgG4 remained completely stable after sting challenges. Monitoring VIT efficacy was only possible in vespid venom allergy, and the sIgG4 threshold for rVes v 5 had the highest sensitivity to confirm tolerance. The BAT inhibition test was the most reliable tool to confirm tolerance on an individual basis.
Currently available tests are unable to distinguish between asymptomatic sensitization and clinically relevant Hymenoptera venom allergy. A reliable serological marker to monitor venom immunotherapy (VIT) does also not exist. Our aim was to find reliable serological markers to predict tolerance to bee and vespid stings. We included 77 asymptomatically sensitized subjects, 85 allergic patients with acute systemic sting reactions, and 61 allergic patients currently treated with VIT. Levels of sIgE and sIgG to bee and vespid venom, rApi m 1, and rVes v 5 were measured immediately after allergic sting reactions or before sting challenges and 4 weeks later. All sting challenges were tolerated. The inhibitory activity was determined using BAT inhibition and ELIFAB assay. Median sIgG levels were 96-fold higher in VIT patients (P < .001) while sIgE/sIgG ratios were consistently lower (P < .001). The ELIFAB assay was paralleled by low sIgE/sIgG ratios in VIT patients, showing markedly higher allergen-blocking capacity (P < .001). An almost complete inhibition of the basophil response was seen in all patients treated with vespid venom, but not in those treated with bee venom. Four weeks after the sting, sIgE and sIgG levels were increased in allergic and asymptomatically sensitized patients, but not in VIT patients. Immunological responses after stings varied in bee and vespid venom-allergic patients. In patients under VIT, sIgE and sIgG remained completely stable after sting challenges. Monitoring VIT efficacy was only possible in vespid venom allergy, and the sIgG threshold for rVes v 5 had the highest sensitivity to confirm tolerance. The BAT inhibition test was the most reliable tool to confirm tolerance on an individual basis.
BackgroundCurrently available tests are unable to distinguish between asymptomatic sensitization and clinically relevant Hymenoptera venom allergy. A reliable serological marker to monitor venom immunotherapy (VIT) does also not exist. Our aim was to find reliable serological markers to predict tolerance to bee and vespid stings.MethodsWe included 77 asymptomatically sensitized subjects, 85 allergic patients with acute systemic sting reactions, and 61 allergic patients currently treated with VIT. Levels of sIgE and sIgG4 to bee and vespid venom, rApi m 1, and rVes v 5 were measured immediately after allergic sting reactions or before sting challenges and 4 weeks later. All sting challenges were tolerated. The inhibitory activity was determined using BAT inhibition and ELIFAB assay.ResultsMedian sIgG4 levels were 96‐fold higher in VIT patients (P < .001) while sIgE/sIgG4 ratios were consistently lower (P < .001). The ELIFAB assay was paralleled by low sIgE/sIgG4 ratios in VIT patients, showing markedly higher allergen‐blocking capacity (P < .001). An almost complete inhibition of the basophil response was seen in all patients treated with vespid venom, but not in those treated with bee venom. Four weeks after the sting, sIgE and sIgG4 levels were increased in allergic and asymptomatically sensitized patients, but not in VIT patients.ConclusionImmunological responses after stings varied in bee and vespid venom‐allergic patients. In patients under VIT, sIgE and sIgG4 remained completely stable after sting challenges. Monitoring VIT efficacy was only possible in vespid venom allergy, and the sIgG4 threshold for rVes v 5 had the highest sensitivity to confirm tolerance. The BAT inhibition test was the most reliable tool to confirm tolerance on an individual basis.
Background Currently available tests are unable to distinguish between asymptomatic sensitization and clinically relevant Hymenoptera venom allergy. A reliable serological marker to monitor venom immunotherapy (VIT) does also not exist. Our aim was to find reliable serological markers to predict tolerance to bee and vespid stings. Methods We included 77 asymptomatically sensitized subjects, 85 allergic patients with acute systemic sting reactions, and 61 allergic patients currently treated with VIT. Levels of sIgE and sIgG4 to bee and vespid venom, rApi m 1, and rVes v 5 were measured immediately after allergic sting reactions or before sting challenges and 4 weeks later. All sting challenges were tolerated. The inhibitory activity was determined using BAT inhibition and ELIFAB assay. Results Median sIgG4 levels were 96‐fold higher in VIT patients (P < .001) while sIgE/sIgG4 ratios were consistently lower (P < .001). The ELIFAB assay was paralleled by low sIgE/sIgG4 ratios in VIT patients, showing markedly higher allergen‐blocking capacity (P < .001). An almost complete inhibition of the basophil response was seen in all patients treated with vespid venom, but not in those treated with bee venom. Four weeks after the sting, sIgE and sIgG4 levels were increased in allergic and asymptomatically sensitized patients, but not in VIT patients. Conclusion Immunological responses after stings varied in bee and vespid venom‐allergic patients. In patients under VIT, sIgE and sIgG4 remained completely stable after sting challenges. Monitoring VIT efficacy was only possible in vespid venom allergy, and the sIgG4 threshold for rVes v 5 had the highest sensitivity to confirm tolerance. The BAT inhibition test was the most reliable tool to confirm tolerance on an individual basis.
Author Laipold, K.
Herzog, S. A.
Vollmann, J.
Möbs, C.
Sturm, G. J.
Schrautzer, C.
Arzt, L.
Reider, N.
Bohle, B.
Pfützner, W.
Bokanovic, D.
Aberer, W.
Author_xml – sequence: 1
  givenname: L.
  orcidid: 0000-0002-5489-2070
  surname: Arzt
  fullname: Arzt, L.
  organization: Medical University of Graz
– sequence: 2
  givenname: D.
  surname: Bokanovic
  fullname: Bokanovic, D.
  organization: Medical University of Graz
– sequence: 3
  givenname: C.
  surname: Schrautzer
  fullname: Schrautzer, C.
  organization: Medical University of Graz
– sequence: 4
  givenname: K.
  surname: Laipold
  fullname: Laipold, K.
  organization: Medical University of Graz
– sequence: 5
  givenname: C.
  surname: Möbs
  fullname: Möbs, C.
  organization: Philipps‐University of Marburg
– sequence: 6
  givenname: W.
  surname: Pfützner
  fullname: Pfützner, W.
  organization: Philipps‐University of Marburg
– sequence: 7
  givenname: S. A.
  surname: Herzog
  fullname: Herzog, S. A.
  organization: Medical University of Graz
– sequence: 8
  givenname: J.
  surname: Vollmann
  fullname: Vollmann, J.
  organization: University of Graz
– sequence: 9
  givenname: N.
  surname: Reider
  fullname: Reider, N.
  organization: Medical University of Innsbruck
– sequence: 10
  givenname: B.
  orcidid: 0000-0002-5105-7985
  surname: Bohle
  fullname: Bohle, B.
  organization: Medical University of Vienna
– sequence: 11
  givenname: W.
  surname: Aberer
  fullname: Aberer, W.
  organization: Medical University of Graz
– sequence: 12
  givenname: G. J.
  surname: Sturm
  fullname: Sturm, G. J.
  email: gunter.sturm@medunigraz.at
  organization: Medical University of Graz
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29171032$$D View this record in MEDLINE/PubMed
BookMark eNp1kc1u3CAUhVGVqpmkXfQFKqRu2oUTsLExyyjqT6SRuskeMfjSMMLgAu7IWXXdVZ4xT1I6M9lELRuQ-M45cO4ZOvHBA0JvKbmgZV0q5y5o03T9C7SijegrIUR7glaEkrZibdOforOUtoQQXgvyCp3WgnJKmnqFft-M4-yDC9-tVg4P1hiI4DUkvIG8A_DY-gQ645_gw_j466GEQSw0nlS24HPCO5vvsPLD_hDmjO3eM99BVNOyv1FpGaccxiIpMW7BCXyy2d7DgNO82ZaA9Bq9NMoleHPcz9Ht50-311-r9bcvN9dX60o35SsVcMqA1wMzbNCt2Whd605xwZVpddf2olc9bwwXoFnf0YFTTTmjAxOtgM405-jDwXaK4ccMKcvRJg3OKQ9hTpKKrmesbvq2oO-fodswR18eJ2vS0k5QVotCvTtS82aEQU7Rjiou8qnkAlweAB1DShGM1DaXJoLPUVknKZF_xyhLMXI_xqL4-EzxZPov9ui-sw6W_4Pyar0-KP4AunOwdw
CitedBy_id crossref_primary_10_1016_j_reval_2021_01_006
crossref_primary_10_1111_pai_13189
crossref_primary_10_21508_1027_4065_2024_69_4_102_108
crossref_primary_10_1007_s00060_018_5737_2
crossref_primary_10_3389_fimmu_2020_01815
crossref_primary_10_1186_s13223_020_0416_4
crossref_primary_10_1097_01_JAA_0000758196_47706_91
crossref_primary_10_1111_all_14747
crossref_primary_10_1111_cea_13237
crossref_primary_10_3390_vaccines9030249
crossref_primary_10_1007_s15007_020_0745_0
crossref_primary_10_1016_j_alit_2020_08_002
crossref_primary_10_1097_ACI_0000000000000580
crossref_primary_10_2217_imt_2020_0326
crossref_primary_10_29262_ram_v69i3_1135
crossref_primary_10_1111_pai_13854
crossref_primary_10_1186_s13223_020_00427_z
crossref_primary_10_1007_s15007_018_1648_1
crossref_primary_10_1111_all_13980
crossref_primary_10_1007_s40629_020_00117_7
crossref_primary_10_1016_j_jaip_2024_10_029
crossref_primary_10_1111_cea_13305
crossref_primary_10_1016_j_jaip_2019_06_008
crossref_primary_10_1007_s00103_020_03224_6
crossref_primary_10_1097_ACI_0000000000000693
crossref_primary_10_3389_fimmu_2018_03131
Cites_doi 10.1111/j.1398-9995.2004.00505.x
10.1111/j.1398-9995.1996.tb04632.x
10.1186/1471-2105-12-77
10.1067/mai.2002.129124
10.1016/S0140-6736(77)91953-5
10.1016/j.jaci.2014.09.049
10.1371/journal.pone.0020842
10.1159/000161586
10.1016/0091-6749(91)90095-6
10.1371/journal.pone.0146021
10.1016/j.jaci.2016.04.024
10.1067/mai.2001.120013
10.1016/0091-6749(79)90075-7
10.1016/j.jaci.2012.07.056
10.1111/all.12606
10.1016/0091-6749(83)90503-1
10.1016/S0091-6749(98)70167-8
10.1016/j.jaci.2013.05.025
10.1111/j.1398-9995.1994.tb02660.x
10.1111/j.1398-9995.2004.00400.x
10.1111/j.1365-2222.1993.tb01791.x
10.1111/j.1398-9995.1996.tb00110.x
10.1016/j.jaci.2012.05.047
10.1016/j.jaci.2013.10.046
10.1016/S0091-6749(00)90092-7
10.1111/all.13154
10.1111/j.1398-9995.2012.02817.x
10.1111/j.1398-9995.1996.tb04596.x
10.1016/j.jaci.2011.12.975
10.1046/j.1365-2222.1998.00411.x
10.1111/j.1365-2222.1986.tb01963.x
10.1111/j.1365-2222.2009.03303.x
10.1111/j.1398-9995.2011.02745.x
10.1016/S0091-6749(05)80019-3
10.1016/S0091-6749(97)70271-9
10.1016/j.jaci.2013.10.060
10.1046/j.1365-2222.2000.00863.x
10.1111/j.1398-9995.1989.tb04172.x
10.1007/s12026-009-8160-3
10.1111/all.12568
ContentType Journal Article
Copyright 2017 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
Copyright © 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Copyright_xml – notice: 2017 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
– notice: Copyright © 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7T5
H94
K9.
7X8
DOI 10.1111/all.13368
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Immunology Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
AIDS and Cancer Research Abstracts

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1398-9995
EndPage 1231
ExternalDocumentID 29171032
10_1111_all_13368
ALL13368
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID .3N
.GA
.GJ
.Y3
05W
0R~
10A
1OB
1OC
23M
2WC
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5RE
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8F7
8UM
930
A01
A03
AAESR
AAEVG
AAHQN
AAIPD
AAKAS
AAMMB
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABEML
ABJNI
ABLJU
ABOCM
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZCM
ADZMN
AEFGJ
AEIGN
AEIMD
AENEX
AEUYR
AEYWJ
AFBPY
AFEBI
AFFNX
AFFPM
AFGKR
AFRAH
AFWVQ
AFZJQ
AGHNM
AGQPQ
AGXDD
AGYGG
AHBTC
AHEFC
AHMBA
AIACR
AIDQK
AIDYY
AITYG
AIURR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
AOETA
ATUGU
AZBYB
AZFZN
AZVAB
BAFTC
BAWUL
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DC6
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
E3Z
EBS
EJD
EMOBN
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
FZ0
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
P6G
PALCI
PQQKQ
Q.N
Q11
QB0
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
TEORI
TR2
UB1
V9Y
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WIN
WOHZO
WOW
WQJ
WVDHM
WXI
WXSBR
XG1
Y6R
ZGI
ZXP
ZZTAW
~IA
~KM
~WT
AAHHS
AAYXX
ACCFJ
AEEZP
AEQDE
AIWBW
AJBDE
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7T5
H94
K9.
7X8
ID FETCH-LOGICAL-c3538-e714e72d4f4dc5fbcc2c6a797af5c65898a873f79ec4861d71c1741d4959e6f3
IEDL.DBID DR2
ISSN 0105-4538
1398-9995
IngestDate Fri Jul 11 00:31:30 EDT 2025
Fri Jul 25 09:24:24 EDT 2025
Thu Apr 03 07:05:02 EDT 2025
Tue Jul 01 04:15:06 EDT 2025
Thu Apr 24 23:12:06 EDT 2025
Wed Aug 20 07:25:54 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords IgG4
basophil activation test
hymenoptera venom allergy
venom immunotherapy
IgE
Language English
License http://onlinelibrary.wiley.com/termsAndConditions#vor
2017 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3538-e714e72d4f4dc5fbcc2c6a797af5c65898a873f79ec4861d71c1741d4959e6f3
Notes Funding information
This study was supported by a research grant from the Philipps‐University Marburg to C.M
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-5105-7985
0000-0002-5489-2070
PMID 29171032
PQID 2051691429
PQPubID 34098
PageCount 9
ParticipantIDs proquest_miscellaneous_1968442385
proquest_journals_2051691429
pubmed_primary_29171032
crossref_citationtrail_10_1111_all_13368
crossref_primary_10_1111_all_13368
wiley_primary_10_1111_all_13368_ALL13368
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate June 2018
2018-06-00
2018-Jun
20180601
PublicationDateYYYYMMDD 2018-06-01
PublicationDate_xml – month: 06
  year: 2018
  text: June 2018
PublicationDecade 2010
PublicationPlace Denmark
PublicationPlace_xml – name: Denmark
– name: Zurich
PublicationTitle Allergy (Copenhagen)
PublicationTitleAlternate Allergy
PublicationYear 2018
Publisher Blackwell Publishing Ltd
Publisher_xml – name: Blackwell Publishing Ltd
References 1993; 23
1998; 28
1989; 44
2002; 110
2015; 70
2015; 10
1986; 16
1996; 51
2014; 24
1994; 49
2008; 148
1983; 72
2011; 12
2001; 108
2014; 133
2011; 6
2012; 129
1992; 90
2017; 72
2012; 130
2010; 47
2015; 135
2000; 105
1991; 88
2004; 59
2000; 30
1997; 100
1977; 1
2016; 138
2013; 132
1979; 64
2012; 67
1998; 101
2009; 39
e_1_2_8_28_1
e_1_2_8_29_1
e_1_2_8_24_1
e_1_2_8_25_1
e_1_2_8_26_1
e_1_2_8_27_1
Hayashi Y (e_1_2_8_31_1) 2014; 24
e_1_2_8_3_1
e_1_2_8_2_1
e_1_2_8_5_1
e_1_2_8_4_1
e_1_2_8_7_1
e_1_2_8_6_1
e_1_2_8_9_1
e_1_2_8_8_1
e_1_2_8_20_1
e_1_2_8_21_1
e_1_2_8_42_1
e_1_2_8_22_1
e_1_2_8_23_1
e_1_2_8_41_1
e_1_2_8_40_1
e_1_2_8_17_1
e_1_2_8_18_1
e_1_2_8_39_1
e_1_2_8_19_1
e_1_2_8_13_1
e_1_2_8_36_1
e_1_2_8_14_1
e_1_2_8_35_1
e_1_2_8_15_1
e_1_2_8_38_1
e_1_2_8_16_1
e_1_2_8_37_1
e_1_2_8_32_1
e_1_2_8_10_1
e_1_2_8_11_1
e_1_2_8_34_1
e_1_2_8_12_1
e_1_2_8_33_1
e_1_2_8_30_1
References_xml – volume: 23
  start-page: 647
  year: 1993
  end-page: 660
  article-title: Venom‐specific IgG antibodies in bee and wasp allergy: lack of correlation with protection from stings
  publication-title: Clin Exp Allergy
– volume: 133
  start-page: 1383
  year: 2014
  end-page: 1389
  article-title: Component resolution reveals additional major allergens in patients with honeybee venom allergy
  publication-title: J Allergy Clin Immunol
– volume: 30
  start-page: 1166
  year: 2000
  end-page: 1171
  article-title: Diagnosis of venom allergy by flow cytometry. Correlation with clinical history, skin tests, specific IgE, histamine and leukotriene C4 release
  publication-title: Clin Exp Allergy
– volume: 133
  start-page: 1635
  year: 2014
  end-page: 1643
  article-title: Sensitization to Hymenoptera venoms is common, but systemic sting reactions are rare
  publication-title: J Allergy Clin Immunol
– volume: 49
  start-page: 272
  year: 1994
  end-page: 280
  article-title: A comparative study of IgG subclass antibodies in patients allergic to wasp or bee venom
  publication-title: Allergy
– volume: 59
  start-page: 1110
  year: 2004
  end-page: 1117
  article-title: The CD63 basophil activation test in Hymenoptera venom allergy: a prospective study
  publication-title: Allergy
– volume: 72
  start-page: 1419
  year: 2017
  end-page: 1422
  article-title: Questionable diagnostic benefit of the commercially available panel of bee venom components
  publication-title: Allergy
– volume: 72
  start-page: 376
  year: 1983
  end-page: 385
  article-title: Antibodies to purified bee venom proteins and peptides. II. A detailed study of changes in IgE and IgG antibodies to individual bee venom antigens
  publication-title: J Allergy Clin Immunol
– volume: 47
  start-page: 273
  year: 2010
  end-page: 284
  article-title: IgE antibody‐specific activity in human allergic disease
  publication-title: Immunol Res
– volume: 44
  start-page: 412
  year: 1989
  end-page: 418
  article-title: Predictive value of venom‐specific IgE, IgG and IgG subclass antibodies in patients on immunotherapy with honey bee venom
  publication-title: Allergy
– volume: 6
  start-page: e20842
  year: 2011
  article-title: Inconsistent Results of Diagnostic Tools Hamper the Differentiation between Bee and Vespid Venom Allergy
  publication-title: PLoS One
– volume: 138
  start-page: 1663
  year: 2016
  end-page: 1671
  article-title: Predominant Api m 10 sensitization as risk factor for treatment failure in honey bee venom immunotherapy
  publication-title: J Allergy Clin Immunol
– volume: 67
  start-page: 217
  year: 2012
  end-page: 226
  article-title: Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy
  publication-title: Allergy
– volume: 67
  start-page: 822
  year: 2012
  end-page: 830
  article-title: Basophil response and the induction of a tolerance in venom immunotherapy: a long‐term sting challenge study
  publication-title: Allergy
– volume: 51
  start-page: 216
  year: 1996
  end-page: 225
  article-title: The sting challenge test in Hymenoptera venom allergy. Position paper of the Subcommittee on Insect Venom Allergy of the European Academy of Allergology and Clinical Immunology
  publication-title: Allergy
– volume: 59
  start-page: 589
  year: 2004
  end-page: 595
  article-title: Specific immunotherapy in honeybee venom allergy: a comparative study using aqueous and aluminium hydroxide adsorbed preparations
  publication-title: Allergy
– volume: 148
  start-page: 261
  year: 2008
  end-page: 264
  article-title: Asymptomatic Sensitization to Hymenoptera Venom Is Related to Total Immunoglobulin E Levels
  publication-title: Int Arch Allergy Immunol
– volume: 129
  start-page: 1406
  year: 2012
  end-page: 1408
  article-title: High sensitivity of CAP‐FEIA rVes v 5 and rVes v 1 for diagnosis of Vespula venom allergy
  publication-title: J Allergy Clin Immunol
– volume: 16
  start-page: 317
  year: 1986
  end-page: 322
  article-title: Sub‐class of IgG anti‐bee venom antibody produced during bee venom immunotherapy and its relationship to long‐term protection from bee stings and following termination of venom immunotherapy
  publication-title: Clin Allergy
– volume: 51
  start-page: 372
  year: 1996
  end-page: 377
  article-title: IgE antibodies to Hymenoptera venoms in the serum are common in the general population and are related to indications of atopy
  publication-title: Allergy
– volume: 110
  start-page: 928
  year: 2002
  end-page: 933
  article-title: Rush Hymenoptera venom immunotherapy: a safe and practical protocol for high‐risk patients
  publication-title: J Allergy Clin Immunol
– volume: 28
  start-page: 1292
  year: 1998
  end-page: 1298
  article-title: Bee sting allergy in beekeepers
  publication-title: Clin Exp Allergy
– volume: 100
  start-page: 767
  year: 1997
  end-page: 770
  article-title: Discontinuation of yellow jacket venom immunotherapy: follow‐up of 75 patients by means of deliberate sting challenge
  publication-title: J Allergy Clin Immunol
– volume: 12
  start-page: 77
  year: 2011
  article-title: pROC: an open‐source package for R and S+ to analyze and compare ROC curves
  publication-title: BMC Bioinformatics
– volume: 90
  start-page: 386
  year: 1992
  end-page: 393
  article-title: Clinical correlation of the venom‐specific IgG antibody level during maintenance venom immunotherapy
  publication-title: J Allergy Clin Immunol
– volume: 88
  start-page: 339
  year: 1991
  end-page: 348
  article-title: Clinical and immunologic follow‐up of patients who stop venom immunotherapy
  publication-title: J Allergy Clin Immunol
– volume: 132
  start-page: 1003
  year: 2013
  end-page: 1005
  article-title: Cell‐free detection of allergen‐IgE cross‐linking with immobilized phase CD23: inhibition by blocking antibody responses after immunotherapy
  publication-title: J Allergy Clin Immunol
– volume: 108
  start-page: 1045
  year: 2001
  end-page: 1052
  article-title: Antibody binding to venom carbohydrates is a frequent cause for double positivity to honeybee and yellow jacket venom in patients with stinging‐insect allergy
  publication-title: J Allergy Clin Immunol
– volume: 70
  start-page: 457
  year: 2015
  end-page: 460
  article-title: Comparable profiles of serum histamine and IgG4 levels in allergic beekeepers
  publication-title: Allergy
– volume: 70
  start-page: 715
  year: 2015
  end-page: 719
  article-title: Decline of Ves v 5‐specific blocking capacity in wasp venom‐allergic patients after stopping allergen immunotherapy
  publication-title: Allergy
– volume: 64
  start-page: 5
  year: 1979
  end-page: 12
  article-title: Insect allergy: the state of the art
  publication-title: J Allergy Clin Immunol
– volume: 1
  start-page: 466
  year: 1977
  end-page: 469
  article-title: Incidence and severity of anaphylactoid reactions to colloid volume substitutes
  publication-title: Lancet
– volume: 24
  start-page: 192
  year: 2014
  end-page: 194
  article-title: Usefulness of specific‐IgG4 to Hymenoptera venom in the natural history of hymenoptera stings
  publication-title: J Investig Allergol Clin Immunol
– volume: 105
  start-page: 385
  year: 2000
  end-page: 390
  article-title: Survey of patients after discontinuing venom immunotherapy
  publication-title: J Allergy Clin Immunol
– volume: 39
  start-page: 1353
  year: 2009
  end-page: 1357
  article-title: Time course of serum inhibitory activity for facilitated allergen‐IgE binding during bee venom immunotherapy in children
  publication-title: Clin Exp Allergy
– volume: 10
  start-page: e0146021
  year: 2015
  article-title: Dose‐Response Analysis Using R
  publication-title: PLoS One
– volume: 130
  start-page: 817
  year: 2012
  article-title: Ves v 5 can establish the diagnosis in patients without detectable specific IgE to wasp venom and a possible north‐south difference in Api m 1 sensitization in Europe
  publication-title: J Allergy Clin Immunol
– volume: 51
  start-page: 540
  year: 1996
  end-page: 546
  article-title: Honeybee venom allergy: immunoblot studies in allergic patients after immunotherapy and before sting challenge
  publication-title: Allergy
– volume: 135
  start-page: 913
  year: 2015
  end-page: 921
  article-title: Basophil expression of diamine oxidase: a novel biomarker of allergen immunotherapy response
  publication-title: J Allergy Clin Immunol
– volume: 101
  start-page: 606
  year: 1998
  end-page: 612
  article-title: Long‐term protection after stopping venom immunotherapy: results of re‐stings in 200 patients
  publication-title: J Allergy Clin Immunol
– volume: 130
  start-page: 1108
  year: 2012
  end-page: 1116
  article-title: Birch pollen immunotherapy results in long‐term loss of Bet v 1‐specific TH2 responses, transient TR1 activation, and synthesis of IgE‐blocking antibodies
  publication-title: J Allergy Clin Immunol
– ident: e_1_2_8_37_1
  doi: 10.1111/j.1398-9995.2004.00505.x
– ident: e_1_2_8_7_1
  doi: 10.1111/j.1398-9995.1996.tb04632.x
– volume: 24
  start-page: 192
  year: 2014
  ident: e_1_2_8_31_1
  article-title: Usefulness of specific‐IgG4 to Hymenoptera venom in the natural history of hymenoptera stings
  publication-title: J Investig Allergol Clin Immunol
– ident: e_1_2_8_28_1
  doi: 10.1186/1471-2105-12-77
– ident: e_1_2_8_12_1
  doi: 10.1067/mai.2002.129124
– ident: e_1_2_8_23_1
  doi: 10.1016/S0140-6736(77)91953-5
– ident: e_1_2_8_40_1
  doi: 10.1016/j.jaci.2014.09.049
– ident: e_1_2_8_4_1
  doi: 10.1371/journal.pone.0020842
– ident: e_1_2_8_8_1
  doi: 10.1159/000161586
– ident: e_1_2_8_13_1
  doi: 10.1016/0091-6749(91)90095-6
– ident: e_1_2_8_27_1
  doi: 10.1371/journal.pone.0146021
– ident: e_1_2_8_34_1
  doi: 10.1016/j.jaci.2016.04.024
– ident: e_1_2_8_10_1
  doi: 10.1067/mai.2001.120013
– ident: e_1_2_8_16_1
  doi: 10.1016/0091-6749(79)90075-7
– ident: e_1_2_8_5_1
  doi: 10.1016/j.jaci.2012.07.056
– ident: e_1_2_8_26_1
  doi: 10.1111/all.12606
– ident: e_1_2_8_17_1
  doi: 10.1016/0091-6749(83)90503-1
– ident: e_1_2_8_32_1
  doi: 10.1016/S0091-6749(98)70167-8
– ident: e_1_2_8_25_1
  doi: 10.1016/j.jaci.2013.05.025
– ident: e_1_2_8_21_1
  doi: 10.1111/j.1398-9995.1994.tb02660.x
– ident: e_1_2_8_3_1
  doi: 10.1111/j.1398-9995.2004.00400.x
– ident: e_1_2_8_19_1
  doi: 10.1111/j.1365-2222.1993.tb01791.x
– ident: e_1_2_8_22_1
  doi: 10.1111/j.1398-9995.1996.tb00110.x
– ident: e_1_2_8_42_1
  doi: 10.1016/j.jaci.2012.05.047
– ident: e_1_2_8_9_1
  doi: 10.1016/j.jaci.2013.10.046
– ident: e_1_2_8_11_1
  doi: 10.1016/S0091-6749(00)90092-7
– ident: e_1_2_8_33_1
  doi: 10.1111/all.13154
– ident: e_1_2_8_14_1
  doi: 10.1111/j.1398-9995.2012.02817.x
– ident: e_1_2_8_15_1
  doi: 10.1111/j.1398-9995.1996.tb04596.x
– ident: e_1_2_8_35_1
  doi: 10.1016/j.jaci.2011.12.975
– ident: e_1_2_8_29_1
  doi: 10.1046/j.1365-2222.1998.00411.x
– ident: e_1_2_8_36_1
  doi: 10.1111/j.1365-2222.1986.tb01963.x
– ident: e_1_2_8_39_1
  doi: 10.1111/j.1365-2222.2009.03303.x
– ident: e_1_2_8_6_1
  doi: 10.1111/j.1398-9995.2011.02745.x
– ident: e_1_2_8_20_1
  doi: 10.1016/S0091-6749(05)80019-3
– ident: e_1_2_8_38_1
  doi: 10.1016/S0091-6749(97)70271-9
– ident: e_1_2_8_41_1
  doi: 10.1016/j.jaci.2013.10.060
– ident: e_1_2_8_2_1
  doi: 10.1046/j.1365-2222.2000.00863.x
– ident: e_1_2_8_18_1
  doi: 10.1111/j.1398-9995.1989.tb04172.x
– ident: e_1_2_8_24_1
  doi: 10.1007/s12026-009-8160-3
– ident: e_1_2_8_30_1
  doi: 10.1111/all.12568
SSID ssj0007290
Score 2.3913274
Snippet Background Currently available tests are unable to distinguish between asymptomatic sensitization and clinically relevant Hymenoptera venom allergy. A reliable...
Currently available tests are unable to distinguish between asymptomatic sensitization and clinically relevant Hymenoptera venom allergy. A reliable...
BackgroundCurrently available tests are unable to distinguish between asymptomatic sensitization and clinically relevant Hymenoptera venom allergy. A reliable...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1223
SubjectTerms Adolescent
Adult
Aged
Aged, 80 and over
Allergens
Allergens - immunology
Allergies
Antibody Specificity - immunology
Arthropod Venoms - immunology
Asymptomatic Diseases
basophil activation test
Bees
Biological Variation, Population
Female
Humans
hymenoptera venom allergy
Hypersensitivity - diagnosis
Hypersensitivity - etiology
Hypersensitivity - therapy
IgE
IgG4
Immunoassay
Immunoglobulin E
Immunoglobulin E - blood
Immunoglobulin E - immunology
Immunoglobulin G - blood
Immunoglobulin G - immunology
Immunological tolerance
Immunology
Immunotherapy
Insect Bites and Stings - complications
Insect Bites and Stings - immunology
Male
Middle Aged
Phenotype
Sensitivity and Specificity
Stings
Venom
venom immunotherapy
Young Adult
Title Immunological differences between insect venom‐allergic patients with and without immunotherapy and asymptomatically sensitized subjects
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fall.13368
https://www.ncbi.nlm.nih.gov/pubmed/29171032
https://www.proquest.com/docview/2051691429
https://www.proquest.com/docview/1968442385
Volume 73
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaqHhAX3o-FggziwCUrkjixLU4Voiqo5YCK1ANS5Ke0YptUdXLYnjj31N_IL2HGcQLlISEukaU4tpN4xt-MZz4T8kKVlRLaMMxYVhmTOs-UqmTGKl1zI52XHv2Qhx_q_U_s_XF1vEVeT7kwIz_E7HBDyYj6GgVc6fCTkKv1egkGVo2JvhirhYDo4w_qKJ78K4AfoONSJFYhjOKZn7y6Fv0GMK_i1bjg7N0kn6ehjnEmX5ZDr5fm_BcWx_98l1vkRgKidHecObfJlmvvkGuHaav9Lrl4h5kjk2qk00EqoFZoiu2iqzaAuqSgLruTb18v8VSWM6hNE1droOjkpaq1sdANPV3FNsecr028o8Lm5LTvInEsNLChASPq-9W5szQMGr1E4R452nt79GY_Swc3ZKZEBep4zhwvLPPMmsprYwpTKy658pUByCOFErz0XDrDRJ1bnhswjHILxpp0tS_vk-22a91DQq2VtpA8VwCjGPdK5Z5rK-Cam8IrtiAvpz_YmERqjmdrrJvJuIGhN_HTLsjzuerpyOTxp0o70zRokjCHpniFm4k5rNwL8my-DWKIeyuqdd0QGlBkggE0FdWCPBinz9xLASYx8hbCYOMk-Hv3ze7BQSw8-veqj8l1AHFiDF_bIdv92eCeAFDq9dMoEd8B9S0Thw
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIgGX8qYLBQziwCWrJnFiW-JSIaot7PaAFqkXFDl-SCu2SdUkh-2JMyd-I7-EseMEykNCXCJLcWwn8Yy_GY-_AXgh00zyUlF3YllGVJRxJGUmIpqVOVPCWGGdH3JxnM8-0Lcn2ckWvBrOwvT8EKPDzUmG19dOwJ1D-icpl-v1FC2snF-Bqy6jtzeo3v8gj2LBw4IIArtOeeAVcnE846OXV6PfIOZlxOqXnMOb8HEYbB9p8mnateVUXfzC4_i_b3MLdgIWJQf95LkNW6a6A9cWYbf9Lnw5codHBu1IhlwqqFlICO8iq6pBjUlQY9an3z5_dYlZzrE2CXStDXF-XiIr7Qt115KVb7M_9rXxd2SzOT1ra88diw1sSOOC6tvVhdGk6UrnKGruwfLwzfL1LAq5GyKVOh1qWEwNSzS1VKvMlkolKpdMMGkzhahHcMlZapkwivI81ixWaBvFGu01YXKb3oftqq7MLhCthU4EiyUiKcqslLFlpeZ4jVViJZ3Ay-EXFirwmrv0GutisG9w6IX_tBN4PlY968k8_lRpb5gHRZDnpkj23X5ijIv3BJ6Nt1ES3faKrEzdNQXqMk4RnfJsAg_6-TP2kqBV7KgLcbB-Fvy9--JgPveFh_9e9Slcny0X82J-dPzuEdxATMf7aLY92G7PO_MYcVNbPvHi8R0IZxei
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIlVceFMWChjEgUtWdeLEtjhVlFUL2wqhIvWAFDl-SCu2yapJDtsTZ078Rn4JY-cB5SEhLpGlOLaTzIy_GY8_AzxXSapEoZnfsawiJgsaKZXKiKVFxrW0Tjofhzw6zg4-sDen6ekGvBz2wnT8EGPAzWtGsNdewVfG_aTkarmcooOViStwlWW7wov0_vsf3FG8D7AggMCeE9HTCvk0nvHRy5PRbwjzMmANM87sBnwcxtolmnyatk0x1Re_0Dj-58vchOs9EiV7nejcgg1b3oato36t_Q58OfRbRwbbSIaTVNCukD65iyzKGu0lQXtZnX37_NUfy3KOtUlP1loTH-UlqjShULUNWYQ2u01f63BH1euzVVMF5lhsYE1qn1LfLC6sIXVb-DBRfRdOZq9PXh1E_ckNkU68BbWcMstjwxwzOnWF1rHOFJdcuVQj5pFCCZ44Lq1mIqOGU42eETXorUmbueQebJZVae8DMUaaWHKqEEcx7pSijhdG4JXq2Ck2gRfDH8x1z2ruD9dY5oN3g0PPw6edwLOx6qqj8vhTpZ1BDPJem-s83vWriRSn7gk8HW-jHvrFFVXaqq1ztGSCITYV6QS2O_EZe4nRJ_bEhTjYIAR_7z7fm89D4cG_V30CW-_2Z_n88PjtQ7iGgE50qWw7sNmct_YRgqameByU4zvdFxZa
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Immunological+differences+between+insect+venom-allergic+patients+with+and+without+immunotherapy+and+asymptomatically+sensitized+subjects&rft.jtitle=Allergy+%28Copenhagen%29&rft.au=Arzt%2C+L&rft.au=Bokanovic%2C+D&rft.au=Schrautzer%2C+C&rft.au=Laipold%2C+K&rft.date=2018-06-01&rft.issn=1398-9995&rft.eissn=1398-9995&rft.volume=73&rft.issue=6&rft.spage=1223&rft_id=info:doi/10.1111%2Fall.13368&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0105-4538&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0105-4538&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0105-4538&client=summon